Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. SCLX
stocks logo

SCLX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
26.25M
+60.35%
--
--
26.25M
+81.84%
--
--
12.10M
-18.79%
--
--
Estimates Revision
The market is revising No Change the revenue expectations for Scilex Holding Company (SCLX) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -14.91%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Down
down Image
-14.91%
In Past 3 Month

Valuation Metrics

The current forward P/E ratio for Scilex Holding Co (SCLX.O) is -3.31, compared to its 5-year average forward P/E of -4.17. For a more detailed relative valuation and DCF analysis to assess Scilex Holding Co 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-4.17
Current PE
-3.31
Overvalued PE
7.39
Undervalued PE
-15.73

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
4.17
Current PS
0.00
Overvalued PS
12.54
Undervalued PS
-4.20
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

SCLX News & Events

Events Timeline

(ET)
2025-11-24
06:18:06
Scilex Reveals $20.3M Gross Proceeds from Warrant Exercise
select
2025-11-11 (ET)
2025-11-11
08:34:39
Datavault Board Greenlights Distribution of Dream Bowl Draft Meme Coin
select
2025-11-04 (ET)
2025-11-04
07:41:17
Scilex Secures License for Datavault's AI Technology
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
7.5
11-26Newsfilter
Scilex Acquires $583.3M Stake in Datavault AI via Bitcoin Investment
  • Strategic Investment Completed: Scilex has closed the second tranche of its investment by acquiring 263,914,094 shares of Datavault AI common stock for approximately $583.3 million in Bitcoin, highlighting the company's commitment to blockchain technology.
  • Shareholder Approval: The transaction received approval at Datavault AI's annual meeting on November 24, 2025, ensuring the legality of the share issuance and bolstering investor confidence.
  • Future Collaboration: Scilex and Datavault AI plan to ramp up collaboration to drive Real World Asset tokenization in 2026 and beyond, indicating significant growth potential in emerging markets for both companies.
  • Market Outlook: This investment not only enhances Scilex's asset portfolio but may also increase market acceptance of its non-opioid pain management products through integration with Datavault AI's technology.
[object Object]
Preview
7.5
11-26Newsfilter
Datavault AI Closes $8M Equity Financing with Scilex for 1,237.6 Bitcoin
  • Successful Financing: Datavault AI secured approval at its November 24, 2025, stockholder meeting to close the second tranche of equity financing, raising approximately 1,237.6 Bitcoin, valued at around $8 million, significantly enhancing the company's digital asset reserves.
  • Strategic Collaboration: Scilex Holding Company acquired a pre-funded warrant for approximately 263.91 million shares of Datavault common stock, with both companies aiming for growth by 2026, thereby driving business expansion.
  • Technology Licensing: Datavault granted Scilex a worldwide exclusive license for its AI-driven technology tailored for the biotech sector, which is expected to generate a nonrefundable license fee of $2.5 million per installment, enhancing revenue potential.
  • Market Outlook: The collaboration between the two companies in AI and supercomputing is viewed as a pioneering move in the industry revolution, with Datavault's CEO stating that this financing will accelerate market share acquisition and drive growth in the biotech sector.
[object Object]
Preview
7.5
11-26Globenewswire
Datavault AI Closes $8M Financing with 1,237.6 Bitcoin from Scilex
  • Successful Financing: Datavault AI secured approval at its November 24, 2025, stockholder meeting to close a second tranche financing with Scilex, raising approximately 1,237.6 Bitcoin, which significantly bolsters the company's digital asset reserves.
  • Equity Investment: Scilex purchased a pre-funded warrant exercisable for 263,914,094 shares of Datavault common stock, providing $8 million in funding that will not only support Datavault's platform expansion but also unlock new revenue streams.
  • Strategic Collaboration: The partnership between Datavault and Scilex is deepening, with Scilex obtaining a worldwide exclusive license for Datavault's technology, which is expected to create new business opportunities in the biotech sector and enhance competitive positioning for both companies.
  • Future Outlook: Scilex's CEO emphasized the strategic value of their collaboration, projecting that advanced data analytics and supercomputing capabilities will drive revenue growth, showcasing a first-mover advantage in the AI and supercomputing-driven tech revolution.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Scilex Holding Co (SCLX) stock price today?

The current price of SCLX is 19.4 USD — it has decreased -2.71 % in the last trading day.

arrow icon

What is Scilex Holding Co (SCLX)'s business?

Scilex Holding Company is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company’s commercial products include ZTlidoO (lidocaine topical system) 1.8% for the relief of neuropathic pain associated with postherpetic neuralgia (PHN); ELYXYB, a ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults; and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. In addition, it focuses on product candidates, including SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (SEMDEXAO), an epidural injections formulation to treat lumbosacral radicular pain, or sciatica; SP-103 (lidocaine topical system) 5.4%, a ZTlido formulation, for the treatment of acute pain; and SP-104 (4.5 mg, low-dose naltrexone hydrochloride delayed-release capsules) (SP-104) for fibromyalgia treatment.

arrow icon

What is the price predicton of SCLX Stock?

Wall Street analysts forecast SCLX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for SCLX is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Scilex Holding Co (SCLX)'s revenue for the last quarter?

Scilex Holding Co revenue for the last quarter amounts to 10.56M USD, decreased -26.85 % YoY.

arrow icon

What is Scilex Holding Co (SCLX)'s earnings per share (EPS) for the last quarter?

Scilex Holding Co. EPS for the last quarter amounts to -22.17 USD, increased 1732.23 % YoY.

arrow icon

What changes have occurred in the market's expectations for Scilex Holding Co (SCLX)'s fundamentals?

The market is revising No Change the revenue expectations for Scilex Holding Company (SCLX) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -14.91%.
arrow icon

How many employees does Scilex Holding Co (SCLX). have?

Scilex Holding Co (SCLX) has 115 emplpoyees as of December 05 2025.

arrow icon

What is Scilex Holding Co (SCLX) market cap?

Today SCLX has the market capitalization of 147.16M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free